NASDAQ:RNA

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.

27 October 2025

Biotechnology·Mergers & Acquisitions·NASDAQ:RNA·NYSE:NVS·Pharmaceutical Industry·Stock Market

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis will acquire Avidity Biosciences for $12 billion in cash, offering $72 per share—a 46% premium over Avidity’s last close. Avidity’s stock, which ended Friday at $49.15, is expected to jump sharply when markets open. Novartis is targeting Avidity’s RNA therapies for rare muscle diseases, including a lead drug nearing FDA submission. The deal was announced Sunday, Oct. 26, 2025.

26 October 2025

Mergers & Acquisitions·NASDAQ:RNA·NYSE:NVS·Pharmaceuticals·Stock Market

US Stock Futures Edge Up Despite Weekly Loss Amid Middle East Conflict and Inflation Concerns
March 20, 2026, 4:54 AM EDT. US stock futures rose modestly Friday, with Dow and S&P 500 contracts up 0.2% and Nasdaq 100 futures gaining 0.1%. The markets are set for a fourth straight weekly loss, pressured by rising oil prices linked to the escalating Middle East conflict. Both Dow and Nasdaq Composite are nearing correction levels, about 8% below recent highs. Brent crude futures fell 1.8% to above $106 a barrel, while WTI dropped 2% near $94, following Israel's pledge to aid US efforts to reopen the vital Strait of Hormuz. Fed Chair Jerome Powell's comments tempered expectations for rate cuts despite indications that one could still occur. Earnings season winds down, with GameStop and Carnival set to report next week.